Logo image of LENZ

LENZ THERAPEUTICS INC (LENZ) Stock Overview

NASDAQ:LENZ - US52635N1037 - Common Stock

38.2 USD
+0.83 (+2.22%)
Last: 8/28/2025, 8:22:52 PM
37.98 USD
-0.22 (-0.58%)
After Hours: 8/28/2025, 8:22:52 PM

LENZ Key Statistics, Chart & Performance

Key Statistics
52 Week High41.7
52 Week Low16.54
Market Cap1.09B
Shares28.52M
Float27.74M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.88
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/amc
IPO06-25 2021-06-25
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


LENZ short term performance overview.The bars show the price performance of LENZ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

LENZ long term performance overview.The bars show the price performance of LENZ in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60

The current stock price of LENZ is 38.2 USD. In the past month the price increased by 28.32%. In the past year, price increased by 63.32%.

LENZ THERAPEUTICS INC / LENZ Daily stock chart

LENZ Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.32 692.77B
JNJ JOHNSON & JOHNSON 17.54 422.54B
NVO NOVO-NORDISK A/S-SPONS ADR 14.46 249.32B
AZN ASTRAZENECA PLC-SPONS ADR 18.02 248.01B
NVS NOVARTIS AG-SPONSORED ADR 14.29 244.83B
MRK MERCK & CO. INC. 10.81 207.84B
PFE PFIZER INC 7.26 139.86B
SNY SANOFI-ADR 11.35 121.80B
BMY BRISTOL-MYERS SQUIBB CO 6.97 95.42B
GSK GSK PLC-SPON ADR 8.76 79.50B
ZTS ZOETIS INC 24.89 68.60B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.62 47.28B

About LENZ

Company Profile

LENZ logo image LENZ Therapeutics, Inc. operates as a clinical stage company, which develops ophthalmic pharmaceutical products. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Company Info

LENZ THERAPEUTICS INC

201 Lomas Santa Fe Drive, Suite 300

Solana Beach CALIFORNIA US

Employees: 42

LENZ Company Website

LENZ Investor Relations

Phone: 18589257000

LENZ THERAPEUTICS INC / LENZ FAQ

What is the stock price of LENZ THERAPEUTICS INC today?

The current stock price of LENZ is 38.2 USD. The price increased by 2.22% in the last trading session.


What is the ticker symbol for LENZ THERAPEUTICS INC stock?

The exchange symbol of LENZ THERAPEUTICS INC is LENZ and it is listed on the Nasdaq exchange.


On which exchange is LENZ stock listed?

LENZ stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LENZ THERAPEUTICS INC stock?

14 analysts have analysed LENZ and the average price target is 50.71 USD. This implies a price increase of 32.75% is expected in the next year compared to the current price of 38.2. Check the LENZ THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LENZ THERAPEUTICS INC worth?

LENZ THERAPEUTICS INC (LENZ) has a market capitalization of 1.09B USD. This makes LENZ a Small Cap stock.


How many employees does LENZ THERAPEUTICS INC have?

LENZ THERAPEUTICS INC (LENZ) currently has 42 employees.


What are the support and resistance levels for LENZ THERAPEUTICS INC (LENZ) stock?

LENZ THERAPEUTICS INC (LENZ) has a support level at 37.36 and a resistance level at 40.92. Check the full technical report for a detailed analysis of LENZ support and resistance levels.


Should I buy LENZ THERAPEUTICS INC (LENZ) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LENZ THERAPEUTICS INC (LENZ) stock pay dividends?

LENZ does not pay a dividend.


When does LENZ THERAPEUTICS INC (LENZ) report earnings?

LENZ THERAPEUTICS INC (LENZ) will report earnings on 2025-11-10, after the market close.


What is the Price/Earnings (PE) ratio of LENZ THERAPEUTICS INC (LENZ)?

LENZ THERAPEUTICS INC (LENZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.88).


What is the Short Interest ratio of LENZ THERAPEUTICS INC (LENZ) stock?

The outstanding short interest for LENZ THERAPEUTICS INC (LENZ) is 13.96% of its float. Check the ownership tab for more information on the LENZ short interest.


LENZ Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to LENZ. When comparing the yearly performance of all stocks, LENZ is one of the better performing stocks in the market, outperforming 91.23% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LENZ Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LENZ. While LENZ has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LENZ Financial Highlights

Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS increased by 80.13% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -24.11%
ROE -25.39%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-27.5%
Sales Q2Q%N/A
EPS 1Y (TTM)80.13%
Revenue 1Y (TTM)N/A

LENZ Forecast & Estimates

14 analysts have analysed LENZ and the average price target is 50.71 USD. This implies a price increase of 32.75% is expected in the next year compared to the current price of 38.2.


Analysts
Analysts87.14
Price Target50.71 (32.75%)
EPS Next Y43.69%
Revenue Next YearN/A

LENZ Ownership

Ownership
Inst Owners100.07%
Ins Owners2.76%
Short Float %13.96%
Short Ratio7.86